Evolving Detection Technology Methods
Randy White, PhD
Adnavance Technologies Inc.
High sensitivity and specificity, along with cost reduction, often determine IVD manufacturers' goals in detection technology development and assay production. As a result, the industry has been slow to adopt any new diagnostic technology that has yet to prove itself commercially. However, in order to increase detection limits and improve sensitivity, developers must be willing to explore alternative methods beyond fluorescence and other light amplification technologies.
To learn more about market stratification and open architecture for microarrays and other IVD products, IVD Technology editor Richard Park spoke with Randy White, chief executive officer of Adnavance Technologies Inc. (Vancouver). In this interview, White shares his views on where he thinks detection platform development is headed and the limits of light amplification. He also discusses metallized DNA, the expectations of molecular diagnostics, and the advantages of strategic partnerships.
Balloons Feature Latex Properties without the Risk
Conventional latex is used for a plethora of medical products ranging from disposable gloves to catheters. But, with latex allergy statistics continuing to rise, a host of hospitals are initiating a push to purge conventional latex from the healthcare setting. Tailoring its offerings to meet this emerging demand, TechDevice Corp. has introduced minimally invasive medical balloons that boast the desirable characteristics of latex without the health risk.
Get ready for a brand new Medical Device Link. Soon, the site will feature a new look and easier-to-follow navigation. Our redesigned site will only improve Medical Device Link's ability to provide the medical device industry with the latest news, the most comprehensive supplier directories, and the most in-depth information. 
